Sonic hedgehog signalling proteins are frequently expressed in retinoblastoma and are associated with aggressive clinicopathological features

Ji-Young Choe,1,2 Ji Yun Yun,1,2 Yoon Kyung Jeon,1,3 Se Hoon Kim,4 Ho-Kyung Choung,5 Sohee Oh,6 Mira Park,7 Ji Eun Kim1,7

ABSTRACT

Aims This study aimed to examine the expression of Sonic hedgehog (SHH) signalling proteins in retinoblastoma and to evaluate its clinical significance.

Methods Seventy-nine enucleated retinoblastoma tumours were investigated immunohistochemically using antibodies against SHH pathway proteins, such as SHH, glioma-associated oncogene homologue (GLI) 1, GLI2, GLI3 and ABC binding cassette G2 (ABCG2). Western blotting of SHH signalling proteins was performed in two retinoblastoma cell lines.

Results SHH was expressed in most retinoblastoma cases (78 of 79, 98.7%), with 21 cases (26.6%) showing strong expression. GLI1 and GLI2 were also frequently expressed: 67 of 78 cases (85.9%) and 71 of 77 cases (92.2%), respectively. GLI3, a transcriptional repressor, was expressed at low levels in 23 of the 78 cases (29.5%). High ABCG2 expression was found in 23 of the 78 cases (29.5%). High expression levels of these proteins in retinoblastoma cell lines were confirmed by western blotting. The expression of SHH was associated with advanced stages, local invasion and metastasis (all p<0.05).

Conclusions SHH signalling molecules were frequently expressed in retinoblastoma tumour cells, and high SHH expression was closely related to an advanced disease status. Our results suggest that the SHH signalling pathway may play a role in the progression of retinoblastoma.

INTRODUCTION

Retinoblastoma is the most common primary intraocular malignancy of infancy and childhood, especially before the age of 5 years.1 The incidence of retinoblastoma has been estimated between 1:30 000 and 1:15 000 live births per year.2,3 The pivotal genetic event in the pathogenesis of retinoblastoma is the inactivation of both alleles of the retinoblastoma gene (RB), which is a regulator at the cell-cycle checkpoint between the G1 and S phases.4 However, little is known about additional pathological alterations regarding the biological aggressiveness of the disease, aside from the silencing of the RB.4-6 Chromosomal aberrations, such as an increase in copy number of 6p and 1q or loss of 1p, inactivation of tumour suppressor genes, such as P53, and epigenetic mechanisms, such as aberrant promoter methylation of p16INK4A, have been found in only a small subset of retinoblastoma.7 8 Despite significant research, there are few universally acceptable biomarkers to identify the risk of tumour progression or to predict clinical outcomes in retinoblastoma.

Sonic hedgehog (SHH), a vertebrate homologue of the Drosophila segment polarity gene product hedgehog, is a secreted protein that plays a critical role in cell proliferation and differentiation during embryonic development.9 10 Activation of SHH signalling is mediated by the glioma-associated oncogene homologue (GLI) transcription factors (GLI1, 2 and 3), which trigger several downstream cascade pathways, including multidrug resistant pumps, such as ATP-binding cassette G2 (ABCG2).11-13 Recently, the SHH signalling pathway has been re-emphasised in terms of cancer biology.

Dysregulation of the SHH pathway has been reported in a broad range of cancers, most notably in basal cell carcinoma and medulloblastoma.14 15 However, very few attempts have been made at determining the role of SHH signalling in retinoblastoma. Based on the finding that SHH plays an important role in the differentiation of many embryonic organs, particularly of the retina, we hypothesised that the SHH pathway could be closely involved in the development or progression of retinoblastoma. In this study, we examined the expression profile of SHH signalling proteins in retinoblastoma tumour tissues and the normal retina, and correlated these with various clinicopathological parameters.

METHODS

Seventy-nine consecutive cases of retinoblastoma with enucleation between 1999 and 2011 were enrolled from the Seoul National University Boramae Hospital and the Seoul National University Hospital. Disease recurrence or progression was evaluated by funduscopic examination. The pathology of retinoblastoma was reviewed by two experienced pathologists. The patients were classified according to both the international retinoblastoma staging system and the American Joint Committee on Cancer (AJCC) staging system.16-17 One pair of tissue microarray (TMA) blocks was constructed, each containing 79 tissue cores of 2 mm diameter, sampled from the most representative area of the donor blocks.

Immunohistochemistry (IHC) was performed using the BenchMark automatic immunostaining device (Ventana Medical Systems, Tucson, Arizona, USA) with validated protocols. Heat-induced epitope retrieval was performed using the Ventana CC1 mild reagent for 60 min. Endogenous peroxidase was blocked by incubation with 0.3%
hydrogen peroxide. After treatment with 10% normal goat serum to block non-specific antibody binding, immunohistochemical staining against the antibodies listed in Table 1 was performed.

The interpretation of IHC was also performed by two pathologists. The results of SHH, GLI1 and GLI2 stainings were considered positive if 10% or more of the tumour cells were stained. The expression of SHH was scored as negative, low, intermediate or high and the expression of GLI1 and GLI2 was scored as negative, low or high, depending on the signal intensity. GLI3 was expressed as the percentage of positive tumour cells because the intensity was so homogeneous. Expression of ABCG2 in the tumour cells was compared with that observed in endothelial cells: if equal or higher, then the expression of ABCG2 was considered high; if lower, then the expression of ABCG2 was considered low. Appropriate internal or external controls were used for each antibody.

To validate the results of IHC, western blotting was performed in two retinoblastoma cell lines, Y79 and WERI-Rb-1 (both from American Type Culture Collection, ATCC, Manassas, Virginia, USA), with the same antibodies used for IHC. Cells in log-phase growth were collected, washed in cold phosphate buffered saline and lysed at 4°C in modified radioimmunoprecipitation assay buffer. An equivalent amount of cell lysate (50 μg of protein) resolved by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis was transferred to polyvinylidene difluoride membranes. Non-specific binding was blocked by incubation in Tris-buffered saline supplemented with 0.1% Tween-20 (TBST) and 5% non-fat skimmed milk. The blot was incubated with primary antibodies against SHH, GLI1, GLI2 and GLI3 in TBST containing 5% bovine serum albumin at 4°C for 16 h. The membrane was then washed with TBST and probed with the horseradish peroxidase-conjugated secondary antibody for 2 h at room temperature. The protein–antibody complexes were detected using enhanced chemiluminescence reagents (Amersham, Arlington Heights, Illinois, USA) according to the manufacturer’s recommended protocol. β-Actin (Santa Cruz) was used as an internal positive control.

A statistical analysis was performed using IBM SPSS Statistics, V20.0, for Windows (IBM, New York, USA). Pearson χ² test, Fisher’s exact test or likelihood ratio test for trend was used to assess the associations between each protein expression levels and clinicopathological variables. Statistical significance was defined as p value <0.05. This study was approved by Institutional Review Board of the Seoul National University Boramae Hospital (reference number: 06-2011-157) on July 2011.

RESULTS

Clinical characteristics

The clinical findings of the 79 patients are summarised in Table 2. Mutation of the RB gene was examined in 20 patients using peripheral blood samples, revealing four patients with a mutated RB in germ-line status. Nineteen patients received preoperative chemotherapy and nine of them were resistant to chemotherapy. The mean follow-up period of the patients was 67.4 months (median 69.1 months, range 1–144). Six patients had nodal or distant metastases at the time of enucleation; lymph nodes (1) and leptomeningeal involvement (5). Two patients developed recurrent mass at periportal soft tissue and metastasis to bone marrow about 2 months (1) and 4 months (1) after enucleation and adjuvant chemotherapy.

Table 2 Characteristics of patients with retinoblastoma

<table>
<thead>
<tr>
<th>Variables</th>
<th>Number of patients n (Total=79)</th>
<th>Per cent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis (months)</td>
<td>22.2</td>
<td>(1–99)</td>
</tr>
<tr>
<td>Median (range)</td>
<td>25.9</td>
<td>(1–113)</td>
</tr>
<tr>
<td>Age at operation (months)</td>
<td>44</td>
<td>55.7</td>
</tr>
<tr>
<td>Male sex</td>
<td>2</td>
<td>2.5</td>
</tr>
<tr>
<td>Family history of RB</td>
<td>6</td>
<td>7.6</td>
</tr>
<tr>
<td>Multifocal tumours</td>
<td>18</td>
<td>22.8</td>
</tr>
<tr>
<td>Bilateral tumours</td>
<td>99</td>
<td>123 (113)</td>
</tr>
<tr>
<td>International RB stage</td>
<td>73</td>
<td>92.4</td>
</tr>
<tr>
<td>Stage I</td>
<td>12</td>
<td>15.2</td>
</tr>
<tr>
<td>Stage II</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Stage III</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Stage IV</td>
<td>6</td>
<td>7.6</td>
</tr>
<tr>
<td>Pathological tumour stage</td>
<td>35</td>
<td>44.3</td>
</tr>
<tr>
<td>pT1</td>
<td>23</td>
<td>29.1</td>
</tr>
<tr>
<td>pT2 (a,b)</td>
<td>17</td>
<td>21.5</td>
</tr>
<tr>
<td>pT3 (a,b)</td>
<td>3</td>
<td>3.8</td>
</tr>
<tr>
<td>Unclassifiable</td>
<td>1</td>
<td>1.3</td>
</tr>
<tr>
<td>Optic nerve invasion</td>
<td>32</td>
<td>41.0</td>
</tr>
<tr>
<td>Choroidal invasion</td>
<td>24</td>
<td>30.8</td>
</tr>
<tr>
<td>Extraocular invasion</td>
<td>12</td>
<td>15.2</td>
</tr>
<tr>
<td>Nodal or distant metastasis</td>
<td>6</td>
<td>7.6</td>
</tr>
<tr>
<td>Histopathological features</td>
<td>62</td>
<td>78.5</td>
</tr>
<tr>
<td>Necrosis</td>
<td>59</td>
<td>78.7</td>
</tr>
<tr>
<td>Calcification</td>
<td>45</td>
<td>63.4</td>
</tr>
<tr>
<td>Differentiation</td>
<td>19</td>
<td>24.1</td>
</tr>
<tr>
<td>Further treatment</td>
<td>10</td>
<td>12.7</td>
</tr>
<tr>
<td>Postop. chemoradiotherapy</td>
<td>21</td>
<td>26.6</td>
</tr>
</tbody>
</table>

SHH signalling proteins in normal retina

To determine the baseline expression of SHH-related proteins in a normal retina, we investigated the expression levels of SHH, GLI1, GLI2 and GLI3 in an unaffected portion of enucleated...
compared with the other proteins. Western blotting, which con
eXression of the SHH, GLI1, GLI2 and GLI3 proteins by
cases (29.5%; 29.5%). Cytoplasmic ABCG2 was highly expressed in 23 of 78 cases (29.5%).
4% of GLI3 positivity were found in 23 of the 78 cases
ranged from 0% to 60% (median 0%). Cases with more than
nuclear membrane, and the frequency of GLI3-positive cells
13 cases (16.9%), respectively. GLI3 reactivity was found in the
ganglion cell layer. GLI3 was strongly and diffusely expressed in the stromal cells in the
whole layer (figure 1).

SHH signalling proteins in retinoblastoma
In the retinoblastomas, SHH was found in the cytoplasm of
tumour cells in the majority of cases (78/79, 98.7%), and high
expression was found in 21 cases (26.6%). In contrast to the
polared and restricted expression in the cilia of the normal
retina, the expression of SHH showed a variagated pattern in the
tumour cells, with a diffuse, scattered granular or radiating
pattern from the centre of florets or rosettes. The GLI1 and
GLI2 proteins were expressed in the nuclei of tumour cells in
67 of 78 cases (85.9%) and 71 of 77 cases (92.2%), respectively.
Strong GLI1 and GLI2 expression was noted in 10 (12.8%) and
13 cases (16.9%), respectively. GLI3 reactivity was found in the
nuclear membrane, and the frequency of GLI3-positive cells
ranged from 0% to 60% (median 0%). Cases with more than
4% of GLI3 positivity were found in 23 of the 78 cases (29.5%).
Cytoplasmic ABCG2 was highly expressed in 23 of 78 cases
29.5%; figure 2).

Two retinoblastoma cell lines, Y79 and WERI-Rb-1, showed
expression of the SHH, GLI1, GLI2 and GLI3 proteins by
western blotting, which confirmed the immunohistochemical
results (figure 3). The expression of GLI3 was relatively weak
compared with the other proteins.

SHH signalling proteins and differentiation
Differentiation of retinoblastoma was assessed by histological
features. Each retinoblastoma was categorised as differentiated
or undifferentiated tumours based on the presence of florets or
rosettes and other cytological characteristics. The differentiated
area with florets or rosettes was detected in 45 of the 71 cases
(63.4%).

Although histological evidence of differentiation was found
focally in some cases, SHH expression was found diffusely in
the majority of the cases, regardless of the histological diversity
(figure 4). The expression of GLI1, GLI2 and ABCG2 proteins
was significantly associated with undifferentiated tumours
(p=0.016, p=0.043 and p=0.024, respectively). In addition,
differentiated tumours were associated with early age at enucle-
ation (p=0.007), which coincides with previous studies.18
Undifferentiated tumours showed a tendency of frequent extrao-
cular invasion (p=0.085), metastasis (p=0.002) and high pT
stage by AJCC (p=0.063).

SHH signalling proteins with clinicopathological features
SHH expression was related to the extension of the tumour,
including optic nerve invasion (p=0.004), choroidal invasion
(p=0.023), extraocular invasion (p=0.036), metastasis
(p=0.001), pT stage by AJCC (p=0.029) and the international
retinoblastoma stage (p=0.001; table 3). High expression of
SHH was also associated with absence of preoperative local or
proton therapy (p=0.021). However, the expression of SHH
signalling proteins was not different between patients with or
without adjuvant chemotherapy. SHH expression showed posi-
tive correlations with GLI2 (p=0.012) and ABCG2 expression
(p=0.019).

GLI1 expression was significantly high in bilateral tumours
(p=0.004) and was associated with early age of enucleation
(p=0.029). GLI2 expression was also associated with early age
of diagnosis (p=0.032), GLI1 expression (p≤0.001) and high
ABCG2 expression (p=0.007). Survival analysis was not per-
formed because there was no mortality and only two recur-
cences during the follow-up in our series.

DISCUSSION
This is the first study to investigate the expression of SHH sig-
nalling proteins and to evaluate their clinical significance in a
large number of retinoblastoma samples. In this study, we found
that SHH was expressed diffusely in the cytoplasm of tumour
cells, whereas the normal retina showed expression restricted to
the cilia of photoreceptor cells. Moreover, high SHH expression
was associated with advanced disease status and adverse clinical
outcomes. Our findings suggest that dysregulation of SHH sig-
nalling could be closely involved in the pathogenesis of
retinoblastoma.

Figure 1 Expression of SHH signalling proteins in the normal retina. SHH (A), GLI1 (B), GLI2 (C) and ABCG2 (E) were expressed in the ciliated processes of PR cells. (A) SHH was rarely expressed in normal retina. (B, C) GLI1 was focally positive in the INL, and GLI1 and GLI2 were positive in the cytoplasm of the GCL. (D) GLI3 was expressed only in the stromal cells of the whole layer. (E) ABCG2 was positive in the vascular endothelial cells within the retina. ABCG2, ABC binding cassette G2; GLI, glioma-associated oncogene homologue; SHH, Sonic hedgehog; GCL, ganglion cell layer; PR, photoreceptor; INL, inner nuclear layer.
The role of the RB gene in the development of retinoblastoma has been well established. However, the development of retinoblastoma requires additional molecular alterations to achieve a fully malignant phenotype. The majority of retinoblastomas involve at least one other genetic change in addition to the inactivation of RB. Dysregulation of SHH signalling is one of the possible candidates of an additional pathological alteration needed for retinoblastoma development. SHH signalling is involved in the development of a normal retina, and the loss of SHH expression has been found in dysplastic retinas in trisomy 13. In contrast to the well-polarised, strict localisation in the cell processes of normal photoreceptor cells, SHH expression in retinoblastoma showed a variegated pattern that suggested aberrant expression. Our results support that SHH is involved in the differentiation of tumour cells and that dysregulation of SHH signalling is linked to the pathogenesis of retinoblastoma.

Although retinoblastoma shares several clinicopathological characteristics with medulloblastoma, our findings suggest that the mechanism of SHH signalling could be different to that of medulloblastoma, with the latter displaying ligand-independent regulation. In a portion of medulloblastoma and basal cell carcinomas, SHH signalling is constantly activated without the binding of SHH ligand due to an activating mutation of the SHH receptor; thus, the expression of SHH in tumour cells can be observed in only a few cases. In our study, SHH expression was found in almost all the cases, regardless of differentiation or extent of the disease. These findings suggest that, in contrast to medulloblastoma, regulation of the SHH pathway in retinoblastoma is SHH ligand dependent and that SHH dysregulation might occur in the early stage of tumourigenesis.

Two types of ligand-driven SHH pathways are reported in the literature: paracrine and autocrine signalling. Paracrine signalling has been found in a subset of epithelial cancers, including colon, pancreatic and ovarian cancers. In the paracrine pathway, SHH protein secreted from tumour cells or stromal cells regulates the microenvironment and stimulates immune cells. However, autocrine signalling of the SHH pathway, in which the source of SHH is the tumour cell itself, has been observed in small-cell lung cancer and in some types of malignant lymphomas. We demonstrated SHH expression in retinoblastoma tumour cells by immunohistochemistry and in cell lines by western blotting. Our results support that the regulatory mechanism of SHH signalling in retinoblastoma may be ligand dependent, which is different from that of medulloblastoma. However, whether the mode of SHH activation in retinoblastoma is autocrine or paracrine remains unclear at this time.

We demonstrated the association of SHH protein expression and advanced disease status. Tumours with high expression of SHH ligand showed frequent local invasion, metastasis and advanced stages of both the international retinoblastoma staging system and the AJCC staging system. In addition, patients with high expression of GLI1 and GLI2 were diagnosed with retinoblastoma and underwent enucleation at earlier age. In contrast,
the expression of GLI3 and ABCG2 was not linked to the patients' clinical features. This lack of correlation between GLI3 and clinical features can be partially explained by the diverse functions of GLI proteins. Although all of the proteins examined in our study are known to be transcription factors or a direct downstream target of the SHH pathway, the expression or activation of GLI proteins is controlled by negative feedback between them. Hyperactivated GLI proteins can be suppressed by other GLIs, mainly by GLI3, a transcriptional repressor. Truncated, repressor form of GLI3 predominates in the quiescent hedgehog status. In our study, GLI3 expression was much lower compared with that of other SHH-related proteins, which was also confirmed by western blot assay in cell lines. These findings highly support the idea that SHH signalling is activated in retinoblastoma. We suspect that most nuclear GLI3 in tumour cells might be repressor form; however, this cannot be verified by immunohistochemistry.

In addition, ABCG2 was frequently expressed in tumours and correlated closely to the expression of SHH-related proteins. ABCG2 is an ATP-dependent drug efflux pump that actively exports certain classes of chemotherapeutic drugs. In previous studies, ABCG2 was reported to be highly expressed in many invasive tumours, and the downregulation of ABCG2 by small interfering RNA reversed SHH-induced chemoresistance. Although we could not find a direct association of ABCG2 with therapeutic responses in a small number of patients with chemotherapy, our study may point to the possibility of a link between SHH and

---

**Table 3** Association between expression of SHH signalling proteins and clinicopathological variables

<table>
<thead>
<tr>
<th>Variables (p value*)</th>
<th>SHH</th>
<th>GLI-1</th>
<th>GLI-2</th>
<th>GLI-3</th>
<th>ABCG2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis (&lt;2 years)</td>
<td>0.720</td>
<td>0.120</td>
<td>0.032</td>
<td>0.537</td>
<td>0.342</td>
</tr>
<tr>
<td>Age at enucleation (&lt;2 years)</td>
<td>0.536</td>
<td>0.029</td>
<td>0.127</td>
<td>0.478</td>
<td>0.329</td>
</tr>
<tr>
<td>Sex</td>
<td>0.231</td>
<td>0.351</td>
<td>0.048</td>
<td>0.037</td>
<td>0.223</td>
</tr>
<tr>
<td>Bilateral tumours</td>
<td>0.460</td>
<td>0.004</td>
<td>0.014</td>
<td>0.388</td>
<td>0.623</td>
</tr>
<tr>
<td>International RB stage</td>
<td>0.001</td>
<td>0.581</td>
<td>0.446</td>
<td>0.240</td>
<td>0.240</td>
</tr>
<tr>
<td>Pathological tumour stage</td>
<td>0.029</td>
<td>0.541</td>
<td>0.264</td>
<td>0.024</td>
<td>0.748</td>
</tr>
<tr>
<td>Optic nerve invasion</td>
<td>0.004</td>
<td>0.786</td>
<td>0.634</td>
<td>0.163</td>
<td>0.509</td>
</tr>
<tr>
<td>Choroidal invasion</td>
<td>0.023</td>
<td>0.258</td>
<td>0.140</td>
<td>0.235</td>
<td>0.186</td>
</tr>
<tr>
<td>Extraocular invasion</td>
<td>0.036</td>
<td>0.683</td>
<td>0.541</td>
<td>0.091</td>
<td>0.503</td>
</tr>
<tr>
<td>Nodal or distant metastasis</td>
<td>0.001</td>
<td>0.581</td>
<td>0.446</td>
<td>0.240</td>
<td>0.240</td>
</tr>
<tr>
<td>Differentiated tumour</td>
<td>0.491</td>
<td>0.016</td>
<td>0.043</td>
<td>0.494</td>
<td>0.024</td>
</tr>
<tr>
<td>Preop. chemoradiotherapy</td>
<td>0.140</td>
<td>0.775</td>
<td>0.676</td>
<td>0.324</td>
<td>0.446</td>
</tr>
<tr>
<td>Preop. local/proton therapy</td>
<td>0.021</td>
<td>0.663</td>
<td>0.614</td>
<td>0.530</td>
<td>0.530</td>
</tr>
<tr>
<td>Postop. chemoradiotherapy</td>
<td>0.047</td>
<td>0.928</td>
<td>0.490</td>
<td>0.180</td>
<td>0.360</td>
</tr>
</tbody>
</table>

*Association was compared with Pearson’s χ² test or likelihood ratio test for trend. ABCG2, ABC binding cassette G2; GLI, glioma-associated oncogene homologue; Postop, postoperative; Preop, preoperative; RB, retinoblastoma; SHH, Sonic hedgehog.

---

**Figure 3** Western blotting of SHH signalling proteins in retinoblastoma cell lines. Two retinoblastoma cell lines, Y79 and WERI-Rb-1, show SHH, GLI1, GLI2, and GLI3 expression by western blotting. The expression of GLI3 was relatively weak compared with other proteins. GLI, glioma-associated oncogene homologue; SHH, Sonic hedgehog.

**Figure 4** Immunohistochemical expression of Sonic hedgehog (SHH) in the variously differentiated area of retinoblastoma. (A) SHH expression was observed in both differentiated and undifferentiated tumour areas: area of differentiation (B), undifferentiation (C) and differentiation with clear cytoplasm (D).
therapeutic responses in retinoblastoma. Chemotherapy is the treatment of choice in retinoblastoma because of the strong desire to preserve the eye and due to improved responses. However, risk stratification with regard to relapse or persistent disease is still an unresolved task. Currently, several clinical trials of SHH pathway inhibitors are being conducted for various tumours, and we suggest that retinoblastoma is an additional candidate for SHH-targeted therapy.

In conclusion, we have shown that SHH signalling proteins are frequently expressed in the majority of retinoblastomas; furthermore, high expression of SHH can predict disease progression or adverse outcomes. These data provide a rationale for the further investigation of the SHH signalling pathway as a potential therapeutic target in retinoblastoma.

**Take home messages**

- Sonic hedgehog protein (SHH) was expressed in most cases of retinoblastoma tumours unlike normal retina.
- High expression of SHH was associated with advanced disease status including local invasion and metastasis.
- SHH signalling may participate in the pathogenesis or progression of retinoblastoma.

**Contributors** J-YC and JEK interpreted the pathological features and the immunohistochemistry. MP and JYY undertook experimental works. SO performed statistical analyses. J-YC wrote the paper. All authors reviewed the manuscript and approved the final article.

**Funding** This study was supported by a research fund from Seoul National University Boramae Hospital (03-2010-2) and partly supported by a research fund from Seoul National University Hospital (0520110070).

**Competing interests** None.

**Ethics approval** Institutional Review Board of the Seoul National University Boramae Hospital.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**